A new peritoneal dissemination model established from the human pancreatic cancer cell line.
We established a new cell line, HPC-3P4a, with high peritoneal disseminated potential in nude mice. HPC-3P4a was derived from a human pancreatic carcinoma cell line (HPC-3) that had low capacity for peritoneal dissemination. HPC-3P4a developed peritoneal dissemination in 10 of 11 (90.9%) cases, whereas parental HPC-3 developed peritoneal dissemination in one of six (16.7%) cases. The metastatic foci in the peritoneum showed essentially the same histologic appearance of parental involvement. The tumorigenicity, motility, and adhesive activity of HPC-3P4a to the extracellular matrix were stronger than were those of the HPC-3. In FACS analysis, HPC-3P4a significantly increased the expression of alpha6 and alpha(v)beta5 integrins, while it decreased alpha2 integrin, hCD44H, and hCD44v 10, as compared with HPC-3. The VEGF production of HPC-3P4a was significantly lower than that of HPC-3. Analysis of gene macroarrays showed a variety of cytokines, interleukin, and other immunomodulatory, and their receptors were up-regulated and down-regulated on an mRNA level in HPC-3P4a cells, compared with HPC-3 cells. Intrasplenic injection of HPC-3P4a produced no liver metastasis. We named our original highly liver metastatic cell line HPC-3H4 (previously reported). This HPC-3H4 cell was established by repeated intrasplenic injection from parental cell HPC-3; thus, it developed high liver metastasis. Moreover, HPC-3H4 developed peritoneal dissemination by intra-abdominal injection. In contrast, HPC-3P4a did not develop liver metastasis by intrasplenic injection. These findings are very interesting and might suggest that the process of hematogenous metastasis differed from that of peritoneal dissemination. Thus, this cell line may be useful for investigating the mechanism of peritoneal dissemination in human pancreatic cancer.
Nishimori
H
H
First Department of Surgery, Sapporo Medical University School of Medicine, Japan.
Yasoshima
T
T
Denno
R
R
Shishido
T
T
Hata
F
F
Honma
T
T
Ura
H
H
Yamaguchi
K
K
Yagihashi
A
A
Tanaka
H
H
Kawaguchi
S
S
Kamiguchi
K
K
Isomura
H
H
Sato
N
N
Hirata
K
K
D000230:Adenocarcinoma / Q000473:pathology / Q000556:secondary*; D000818:Animals; D015703:Antigens, CD / Q000235:genetics; D002448:Cell Adhesion; D015815:Cell Adhesion Molecules / Q000032:analysis; D016207:Cytokines / Q000096:biosynthesis / Q000235:genetics; D004247:DNA / Q000032:analysis; D016228:Endothelial Growth Factors / Q000235:genetics; D005260:Female; D005434:Flow Cytometry; D015870:Gene Expression; D006801:Humans; D039503:Integrin alpha6; D007378:Interleukins / Q000235:genetics; D008222:Lymphokines / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D010190:Pancreatic Neoplasms / Q000473:pathology*; D010534:Peritoneal Neoplasms / Q000473:pathology / Q000556:secondary*; D011003:Ploidies; D012333:RNA, Messenger / Q000032:analysis; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D015703:Antigens, CD; D015815:Cell Adhesion Molecules; D016207:Cytokines; D016228:Endothelial Growth Factors; D039503:Integrin alpha6; D007378:Interleukins; D008222:Lymphokines; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D004247:DNA